CO5650230A2 - Composiciones estables de atorvastatina preparadas con granulacion en humedo - Google Patents
Composiciones estables de atorvastatina preparadas con granulacion en humedoInfo
- Publication number
- CO5650230A2 CO5650230A2 CO05124741A CO05124741A CO5650230A2 CO 5650230 A2 CO5650230 A2 CO 5650230A2 CO 05124741 A CO05124741 A CO 05124741A CO 05124741 A CO05124741 A CO 05124741A CO 5650230 A2 CO5650230 A2 CO 5650230A2
- Authority
- CO
- Colombia
- Prior art keywords
- atorvastatin
- dosage form
- unit dosage
- weight
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
Abstract
1.- Una composición farmacéutica de atorvastatina granulada en húmedo con menos de aproximadamente 5 por ciento en peso de un aditivo constituido por una sal de metal alcalino- térreo, que comprende: (a) atorvastatina, en donde dicha atorvastatina es al menos algo desordenada o una mezcla de las formas desordenada y cristalina de atorvastatina o una de sus sales farmacéuticamente aceptables; y (b) un desintegrante o una combinación de desintegrantes, en donde dicha con posición farmacéutica de granulada en húmedo, contiene no más de aproximadamente 3% de lactona de atorvastatina basado en la relación del área del pico de lactona comparada con las áreas integradas de todos los picos relacionados con el fármaco empleando HPLC.2.- La composición farmacéutica granulada en húmedo de la reivindicación 1, en donde dicha composición incluye menos de aproximadamente 0,5% en peso de Tween 80.3.- Una forma de dosificación unitaria preparada a partir de la composición farmacéutica granulada en húmedo de la reivindicación 1.4.- La forma de dosificación unitaria de la reivindicación 4, en donde dicha forma de dosificación unitaria es un comprimido o una cápsula.5.- La forma de dosificación unitaria de la reivindicación 1, en donde dicho desintegrante o combinación de desintegrantes está presente en una proporción entre aproximadamente 1 y 10% (en peso/peso) de dicha composición.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47811903P | 2003-06-12 | 2003-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5650230A2 true CO5650230A2 (es) | 2006-06-30 |
Family
ID=33551806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05124741A CO5650230A2 (es) | 2003-06-12 | 2005-12-09 | Composiciones estables de atorvastatina preparadas con granulacion en humedo |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1635814A1 (es) |
JP (1) | JP2006527260A (es) |
KR (1) | KR100814218B1 (es) |
CN (1) | CN100434069C (es) |
AR (1) | AR044774A1 (es) |
AU (1) | AU2004246868B2 (es) |
BR (1) | BRPI0411344A (es) |
CA (1) | CA2465565A1 (es) |
CO (1) | CO5650230A2 (es) |
MX (1) | MXPA05013281A (es) |
NO (1) | NO20060022L (es) |
NZ (1) | NZ543337A (es) |
RU (1) | RU2332211C2 (es) |
TW (1) | TW200503690A (es) |
WO (1) | WO2004110431A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
CA2691956A1 (en) * | 2007-06-25 | 2008-12-31 | Pharmathen S.A. | Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof |
CA2716671A1 (en) * | 2008-02-27 | 2009-09-03 | Thommen Medical Ag | Implant and method for the manufacture thereof |
JP5714492B2 (ja) * | 2008-09-17 | 2015-05-07 | マイラン インコーポレイテッド | 粒状体、それらの調製方法、およびそれらを含む医薬品 |
HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
RU2014124118A (ru) | 2011-11-15 | 2015-12-27 | Др. Редди'С Лабораторис Лтд. | Фармацевтические препараты, включающие аторвастатин и глимепирид |
CN104069078B (zh) * | 2014-05-22 | 2019-06-11 | 西藏九瑞健康股份有限公司 | 阿托伐他汀钙药物组合物及其制备方法 |
US10085993B2 (en) | 2014-07-25 | 2018-10-02 | Novartis Ag | Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide |
KR101658350B1 (ko) * | 2015-02-06 | 2016-09-30 | 경성대학교 산학협력단 | 고지혈증 치료에 유용한 약학 조성물 |
WO2016145132A1 (en) * | 2015-03-12 | 2016-09-15 | Fmc Corporation | Solid dispersions |
CN109152787A (zh) | 2016-03-31 | 2019-01-04 | 英特塞普特医药品公司 | 具有优越的溶出性的口服制剂 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016693A1 (en) * | 1993-01-19 | 1994-08-04 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
JPH06242003A (ja) * | 1993-02-12 | 1994-09-02 | Nkk Corp | 鉄鋼中のアルミナの粒度測定方法 |
JP3014040B2 (ja) * | 1996-10-30 | 2000-02-28 | 信久 川野 | 食物繊維パン及びその製造法 |
ATE524163T1 (de) * | 2000-04-10 | 2011-09-15 | Teva Pharma | Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren |
US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
EP1226818A1 (en) * | 2001-01-26 | 2002-07-31 | Pfizer Products Inc. | Pharmaceutical dosage forms with enhanced cohesive and compressibility properties |
SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
-
2004
- 2004-04-29 CA CA002465565A patent/CA2465565A1/en not_active Abandoned
- 2004-06-01 JP JP2006516512A patent/JP2006527260A/ja active Pending
- 2004-06-01 RU RU2005136745/15A patent/RU2332211C2/ru not_active IP Right Cessation
- 2004-06-01 BR BRPI0411344-6A patent/BRPI0411344A/pt not_active IP Right Cessation
- 2004-06-01 AU AU2004246868A patent/AU2004246868B2/en not_active Ceased
- 2004-06-01 WO PCT/IB2004/001862 patent/WO2004110431A1/en active Application Filing
- 2004-06-01 CN CNB2004800163910A patent/CN100434069C/zh not_active Expired - Fee Related
- 2004-06-01 MX MXPA05013281A patent/MXPA05013281A/es not_active Application Discontinuation
- 2004-06-01 NZ NZ543337A patent/NZ543337A/en unknown
- 2004-06-01 KR KR1020057023669A patent/KR100814218B1/ko not_active IP Right Cessation
- 2004-06-01 EP EP04735614A patent/EP1635814A1/en not_active Withdrawn
- 2004-06-10 AR ARP040102008A patent/AR044774A1/es unknown
- 2004-06-11 TW TW093116894A patent/TW200503690A/zh unknown
-
2005
- 2005-12-09 CO CO05124741A patent/CO5650230A2/es not_active Application Discontinuation
-
2006
- 2006-01-03 NO NO20060022A patent/NO20060022L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20060020666A (ko) | 2006-03-06 |
TW200503690A (en) | 2005-02-01 |
AR044774A1 (es) | 2005-10-05 |
RU2332211C2 (ru) | 2008-08-27 |
NO20060022L (no) | 2006-01-03 |
CN100434069C (zh) | 2008-11-19 |
KR100814218B1 (ko) | 2008-03-17 |
AU2004246868A1 (en) | 2004-12-23 |
WO2004110431A1 (en) | 2004-12-23 |
NZ543337A (en) | 2008-03-28 |
CN1805741A (zh) | 2006-07-19 |
CA2465565A1 (en) | 2004-12-12 |
BRPI0411344A (pt) | 2006-07-11 |
MXPA05013281A (es) | 2006-03-09 |
JP2006527260A (ja) | 2006-11-30 |
RU2005136745A (ru) | 2006-07-27 |
AU2004246868B2 (en) | 2008-01-17 |
EP1635814A1 (en) | 2006-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5650230A2 (es) | Composiciones estables de atorvastatina preparadas con granulacion en humedo | |
AR038527A1 (es) | Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo | |
CO5640071A2 (es) | Composiciones farmaceuticas de atorvastatina | |
EA200801926A1 (ru) | Таблетки парацетамола с быстрым высвобождением | |
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
CO5390076A1 (es) | Composiciones farmaceuticas | |
CO5640087A2 (es) | Composiciones de farmacos anti-inflamatorios no esteroideos descongestionantes y anti-histaminicos | |
EA200901393A1 (ru) | Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат | |
HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
CO5640072A2 (es) | Composiciones farmaceuticas que comprenden atorvastatina fabricada sin granulacion | |
BRPI0515345A (pt) | comprimidos de liberação gastrointestinal com local e hora controlados de ingrediente ativo | |
ATE386508T1 (de) | Feste orale dosierungsform enthaltend einen resorptionsverstärker | |
ES2194732T3 (es) | Composiciones farmaceuticas orales de liberacion controlada de mesalazina. | |
UY24613A1 (es) | Formula de liberacion controlada que comprende venlafaxina | |
ECSP066990A (es) | Formulaciones con liberación controlada de principio activo que contienen vardenafilo | |
AR050615A1 (es) | Composiciones farmaceuticas para la administracion oral | |
MX2007015480A (es) | Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada. | |
CO5280073A1 (es) | Composiciones | |
AR037930A1 (es) | Formulaciones de acitromicina directamente compresibles | |
UA116334C2 (uk) | Тверді форми дозування бендамустину | |
RS53087B (en) | SOLID PHARMACEUTICAL COMPOSITIONS OF PERMANENT COMPOSITION CONTAINING IRBESARTAN AND AMLODIPINE, THEIR PREPARATION AND THERAPY USE | |
HUP0301390A2 (hu) | Valzartánt tartalmazó orális gyógyászati készítmény | |
MXPA03011317A (es) | Comprimido masticable que comprende paracetamol. | |
RU2006115784A (ru) | Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта | |
ZA200506992B (en) | Fibrate tablet and method for the production thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |